The European First Episode Schizophrenia Trial (EUFEST): comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens.

Trial Profile

The European First Episode Schizophrenia Trial (EUFEST): comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2015

At a glance

  • Drugs Amisulpride; Haloperidol; Olanzapine; Quetiapine; Ziprasidone
  • Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms EUFEST
  • Most Recent Events

    • 01 Sep 2015 Results presented at the 28th Annual Congress of the European College of Neuropsychopharmacology
    • 28 Aug 2010 Subgroup analysis presented at the 23rd Annual Congress of the European College of Neuropsychopharmacology.
    • 01 Dec 2009 Primary endpoints response rate and remission rate on the 'Positive and Negative Syndrome Scale' have been met for amisulpride, olanzapine and ziprasidone versus haloperidol.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top